Active Ingredient History

NOW
  • Now
Lapatinib is a small molecule and a member of the 4-anilinoquinazoline class of kinase inhibitors. It is present as the monohydrate of the ditosylate salt (trade name TYKERB). Lapatinib is dual inhibitor of the EGFR (epidermal growth factor receptor; also called HER1 or ErbB1) and HER2 receptor tyrosine kinases. Lapatinib was developed by GlaxoSmithKline, however, Novartis subsequently acquired all the rights to the drug from GlaxoSmithKline. TYKERB is indicated in combination therapy for the treatment of metastatic breast cancer that overexpresses the HER2 receptor.   NCATS

  • SMILES: CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2
  • InChIKey: BCFGMOOMADDAQU-UHFFFAOYSA-N
  • Mol. Mass: 581.07
  • ALogP: 6.14
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

Australia

$15.6460

United States

$38.8569 - $55.1291
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

cipatinib | fmm | gw-2016 | gw282974x | gw 282974x | gw-282974x | gw572016 | gw 572016 | gw-572016 | gw572016f | gw 572016x | lapatanib | lapatinib | lapatinib ditosilate | lapatinib ditosilate hydrate | lapatinib ditosylate | lapatinib ditosylate hydrate | lapatinib ditosylate monohydrate | lapatinib tosilate | lapatinib tosilate hydrate | n-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine | n-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine | n-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine | tykerb | tyverb

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue